These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19155260)

  • 1. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine.
    Kmietowicz Z
    BMJ; 2009 Jan; 338():b217. PubMed ID: 19155260
    [No Abstract]   [Full Text] [Related]  

  • 2. AstraZeneca pays $520m fine for off label marketing.
    Tanne JH
    BMJ; 2010 Apr; 340():c2380. PubMed ID: 20430836
    [No Abstract]   [Full Text] [Related]  

  • 3. Merck pays $1bn penalty in relation to promotion of rofecoxib.
    Tanne JH
    BMJ; 2011 Nov; 343():d7702. PubMed ID: 22123916
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 6. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of direct-to-consumer advertising.
    Navarro RP
    Manag Care Interface; 1998 Nov; 11(11):79-80, 82. PubMed ID: 10187419
    [No Abstract]   [Full Text] [Related]  

  • 8. Major issues in marketing regulation.
    Pines WL
    Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
    [No Abstract]   [Full Text] [Related]  

  • 9. Serono pays $44m to settle promotion of multiple sclerosis drug.
    Tanne JH
    BMJ; 2011 May; 342():d2922. PubMed ID: 21558361
    [No Abstract]   [Full Text] [Related]  

  • 10. US drug industry bans expensive freebies for MDs, Canada raises fines.
    Sibbald B
    CMAJ; 2002 Sep; 167(5):522. PubMed ID: 12240824
    [No Abstract]   [Full Text] [Related]  

  • 11. Commentary on payment and reimbursement issues affecting the marketing of drugs, medical devices, and biologics, with emphasis on the anti-kickback statute and Stark II.
    Reiss JB
    Food Drug Law J; 1997; 52(1):99-108. PubMed ID: 10346713
    [No Abstract]   [Full Text] [Related]  

  • 12. Maker of growth hormone feels long arm of law.
    Nordenberg T
    FDA Consum; 1999; 33(5):33. PubMed ID: 10522170
    [No Abstract]   [Full Text] [Related]  

  • 13. Lunch with Lilly: who pays?
    Strong C
    Am J Bioeth; 2003; 3(3):62-3. PubMed ID: 14594499
    [No Abstract]   [Full Text] [Related]  

  • 14. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
    Wang B; Studdert DM; Sarpatwari A; Franklin JM; Landon J; Kesselheim AS
    PLoS One; 2017; 12(4):e0175313. PubMed ID: 28388667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Big bad pharma: an ethical analysis of physician-directed and consumer-directed marketing tactics.
    Connors AL
    Albany Law Rev; 2009 Sep; 73(1):243-82. PubMed ID: 20235401
    [No Abstract]   [Full Text] [Related]  

  • 17. Oversight of marketing relationships between physicians and the drug and device industry: a comparative study.
    Jost TS
    Am J Law Med; 2010; 36(2-3):326-42. PubMed ID: 20726399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 19. Selling drugs to the public--should the UK follow the example of the US?
    Frey J
    Br J Gen Pract; 2002 Feb; 52(475):170-1. PubMed ID: 11885831
    [No Abstract]   [Full Text] [Related]  

  • 20. Lilly investigated in US over the marketing of olanzapine.
    Dyer O
    BMJ; 2007 Jan; 334(7586):171. PubMed ID: 17255580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.